Tenders Are Invited For Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accord ...

Work Detail

Pharmaceutical Products - Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Amlodipine + Hct + Ramipril, Atc C09bx03 For The Period February 1St, 2024 - January 31St, 2026. Dak-Gesundheit Assumes That This Procedure Is Due To A Missing Selection Decision And Therefore The Non-Discriminatory Access For Everyone Pharmaceutical Companies Do Not Fall Within The Scope Of Antitrust Procurement Law Falls. Regardless, It Ends Automatically When The Exclusive Contract Comes Into Force For Amlodipine + Hct + Ramipril, Atc C09bx03, As A Result Of A Formal Procurement Procedure In Accordance With The Regulations Of Part 4 Of The Gwb With One Or More Contractual Partners. In Order To Do Justice To The Diversity Of Potential Contractual Partners Within The Framework Of The Approval Model To Become, Will Be Given To Each Pharmaceutical Company During The Term Of The Contract A Framework Agreement Can Be Concluded At Any Time And Under The Same Conditions. The Contractual Documents Required For This Are Available Via The Online Portal Www.Dtvp.De/Center Under 5.1.11. The Link Mentioned Is Available For Download. Requirements For The Conclusion Or Later Accession To The First Came Into Force On February 1St, 2024 The Following Documents Must Be Sent In Full And In A Timely Manner (Available For Download At The Link Mentioned Under 5.1.11) To The Following Department At Dak-Gesundheit: 1. Letter Of Offer 2. Recognition Of The Contractual Requirements Of Dak-Gesundheit, In Particular The Specified Discounts Through Submission Of The Contract Bearing The Name Or Company Stamp By The Interested Party Designated Location. 3. The Completed Appendixes 1 And 2 To The Contract. The Prospective Must Enter The Medicinal Products For The Above-Mentioned Active Ingredient Here, Which Are The Subject Of The Contract Should Be. The Documents Must Be Submitted By Email To: Openhouse@Dak.De Dak-Gesundheit Department Of Medicines (0038 00) Nagelsweg 27-31 20097 Hamburg Die Appendix 2 Must Be Sent As An Excel File To The Email Address Openhouse@Dak.De. Contracts Under This Model And For The Above-Mentioned Active Ingredient Are Being Concluded For The First Time Completed With Effect From February 1St, 2024 And End On January 31St, 2026. Interested Parties Who If You Want To Become A Contractual Partner On This Date, You Have To Submit The Above-Mentioned Documents Submit By Email By The 5Th Of The Previous Month. The Offer Is In Text Form Submit Electronic Offer By E-Mail To Openhouse@Dak.De. Submitting The Offer By Post Is Not Part Of This Procedure Intended. Please Do Not Submit The Offer Via The German Procurement Portal. In Order To Meet The Deadline, All Documents Must Be Received Electronically Via Per Email To The Email Address Openhouse@Dak.De Is Sufficient. Later Memberships Are Possible At Any Time. In Order To Do So During The Term Of The In Order To Be Able To Join The Contract On The 1St Or 15Th Of The Following Month, The Above-Mentioned Documents Must Be Submitted. Regardless Of The Desired Membership, Dak-Gesundheit Must Be Submitted By The 5Th Of The Previous Month. Here Too, It Is Important That Dak-G Receives It In A Timely Manner Via Email. Example: The Bidders Desired Entry Should Take Place On July 15Th. (Following Month), The Documents You Would Have To Do This By June 5Th. (Previous Month). Note: The Publication Takes Place Here Using The Form For Open Procedures. As Already Clear Made, This Is Not The Case - The Announcement Had To Be Made For Technical Reasons, As There Is No Suitable One For The Approval Process Form Exists.

Contact Information

Other Detail